A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

October 31, 2025

Conditions

Neoplasms Malignant

Interventions

DRUG

B1962

B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Trial Locations (1)

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Tasly Biopharmaceuticals Co., Ltd.

INDUSTRY